LOGO
This presentation is the property of its rightful owner.
Sponsored Links
1 / 1

TITULO Autores: PowerPoint PPT Presentation


  • 65 Views
  • Uploaded on
  • Presentation posted in: General

LOGO. TITULO Autores: . LOGO. Procedencia y correos electrónicos . ANTECEDENTES:

Download Presentation

TITULO Autores:

An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -

Presentation Transcript


Titulo autores

LOGO

TITULO

Autores:

LOGO

Procedencia y correos electrónicos

ANTECEDENTES:

xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx

IMAGEN O GRAFICA

IMAGEN O GRAFICA

XXXX. 1 XXXXXXXXXXXXXXXXXXXXXXXXXX

XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX

XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX

XXX 4. XXXXXXXXXXXXXXXXXXXXXXXXXXXXX

XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX

JUSTIFICACIÓN:

xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx

IMAGEN, TABLA O GRAFICA

IMAGEN, GRAFICA O TABLA

XXXX 2. XXXXXXXXXXXXXXXXXXXXXXXXXXX

XXXXXXXXXXXXX

CONCLUSIONES:

xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx

XXXX. 1 XXXXXXXXXXXXXXXXXXXXXXXXXX

XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX

HIPOTESIS:

xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx

RESULTADOS:

OBJETIVO:

xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx

IMAGEN, TABLA O GRAFICA

METODOLOGÍA:

XXXXXXX

XXXXXXX

XXXXX

  • BIBLIOGRAFIA:

  • P. Calabresi y A. B. Chabner. 2001. “Fármacos antineoplásicos” en: Goodman & Gilman. Las bases Farmacológicas de la Terapéutica. 10ª Edición. McGraw-Hill Interamericana. 1405-1475.

  • E Groninger, MT de Boer, P Koopmans, D Uges, W Sluiter, A Veerman W, Kamps, S de Graaf. 2005. “Vincristine pharmacokinetics and response to vincristine monotherapy in an up-front window study of the Dutch Childhood Leukaemia Study Group (DCLSG)”. Europ J Cancer; 41:98-103.

  • G Lönnerholm, BM Frost, J Abrahamsson, M Behrendtz, A Castor, E Forestier, M Heyman, DRA Uges and SSN de Graaf. 2008. “Vincristine pharmacokinetics is related to clinical outcome in children with standard risk acute lymphoblastic leukemia”. Br J Haematoy; 142(4): 616-621.

  • D Levêque and F Jehl. 2007. “Molecular Pharmacokinetics of Catharanthus (Vinca) Alkaloids”. J ClinPharmacol; 47:579-588.

  • DCh Scripture y DW Figg. 2006. “Drug interactions in cancer therapy”. Nature Reviews; 6:546-558.

  • JB Dennison, P Kulanthaivel, RJ Barbuch, JL Renbarger, WJ Ehlhardt, SD Hall. 2006. “Selective Metabolism of Vincristine in Vitro by CYP3A5. Drug MetabolDisp”; 34:1317-1327.

  • JB Dennison, MA Mohutsky, RJ Barbuch, SA Wrighton, SD Hall. 2008.“Apparent High CYP3A5 expression is required for significant metabolism of vincristine by human cryopreserved hepatocytes”JPharmacol ExpTher;1-35

  • D Levêque and F Jehl. 2007. “Molecular Pharmacokinetics of Catharanthus (Vinca) Alkaloids”. J ClinPharmacol; 47:579-588.

  • CCO. Cancer Care Ontario. 2006/2007. “Vincristine. CCO Formulary”. Revised.

  • JE Estlin, M Ronghe, AAG Burke, MS Yule. 2000. “The Clinical and Cellular Pharmacology of Vincristine, Corticosteroides, L-asparaginase, Anthracyclines and Cyclophosphamide in Relation to Childhood Acute Lymphoblastic Leukaemia”. Br J Haematol; 110:780-790.

XXXXX

XXX. 3 XXXXXXXXXXXXXXXXXXXXXXXXXXXXXX

XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX

XXXXXXXXXXXXXXXXXXXXXXX

0

XXXXX

24

XXXXXXXXXXXXXX

IMAGEN, GRAFICA O TABLA

XXXXXXXX

XXXXXXXXX

XXXXXXXXXX

grafica

o imagen

XXX1. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX

XXXXXXXXXXXXXXXXXXXX

horas


  • Login